Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27557955 | 0.86 | KDM4E (0.41) | KDM4EPOLBGAAALDH1A1HSD17B10 | |
| SCHEMBL13561978 | 0.86 | KDM4E (0.51) | KDM4EPOLBGAAALDH1A1HSD17B10 | |
| SCHEMBL1478662 | 0.84 | ALDH1A1 (0.47) | KDM4EPOLBALDH1A1HSD17B10HPGD | |
| SCHEMBL18073572 | 0.84 | KDM4E (0.41) | KDM4EPOLBGAAALDH1A1HSD17B10 | |
| SCHEMBL857226 | 0.82 | KDM4E (0.65) | KDM4EPOLBGAAALDH1A1HSD17B10 | |
| SCHEMBL1355241 | 0.81 | KDM4E (0.49) | KDM4EPOLBGAAALDH1A1HSD17B10 | |
| SCHEMBL856900 | 0.81 | KDM4E (0.58) | KDM4EPOLBGAAALDH1A1HSD17B10 | |
| SCHEMBL28415472 | 0.80 | ALDH1A1 (0.59) | KDM4EPOLBGAAALDH1A1HSD17B10 | |
| SCHEMBL11257711 | 0.80 | ALDH1A1 (0.47) | KDM4EPOLBGAAALDH1A1HSD17B10 | |
| SCHEMBL25208567 | 0.79 | KDM4E (0.46) | KDM4EPOLBGAAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3078660-B1 | NOVEL QUINAZOLINE DERIVATIVE | MYCHUNTER THERAPEUTICS INC (JP) | 2022-07-13 | — | — | EP | disclosed |
| US-9682961-B2 | Quinazoline derivative | CARNA BIOSCIENCES, INC. (JP) | 2017-06-20 | — | — | US | disclosed |
| EP-3078660-A1 | NOVEL QUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2016-10-12 | — | — | EP | disclosed |
| US-20160264555-A1 | NOVEL QUINAZOLINE DERIVATIVE | NATIONAL CANCER CENTER (JP) | 2016-09-15 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| EP-2024342-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | Pfizer Products Incorporated (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | KDM4E 2041/4885POLB 4744/4885GAA 2711/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | KDM4E 2041/4885POLB 4744/4885GAA 2711/4885 |
| US-20160264555-A1 | NOVEL QUINAZOLINE DERIVATIVE | WNT1, CTNNB1, CTNND1 | KDM4E 2190/4885POLB 2859/4885GAA 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.